Quince Therapeutics Q2 net loss $27.7M; Phase 3 NEAT on track for Q4 2025 topline

Quince Therapeutics, Inc.

2024-Q2 EPS reported -$0.90

Cash $59.4M at June 30; expects runway into 2026 through Phase 3 NEAT topline results.
Net loss $27.7M ($0.64/share) includes $17.1M goodwill impairment; R&D $4.2M, G&A $4.7M.
Phase 3 NEAT enrolled 7 patients; topline results expected Q4 2025; NDA/MAA in 2026 if positive.
FDA Fast Track for EryDex in A-T; diagnosed U.S. patients estimated at ~4,600 (up from ~3,400).
Planning DMD proof-of-concept study in 2025; evaluating partnerships for ex-U.S. rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.